Inflammation in Alzheimer Disease—A Brief Review of the Basic Science and Clinical Literature

  1. Joseph Rogers3
  1. 1Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305-5235
  2. 2Geriatric Research Education and Clinical Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304
  3. 3Banner Sun Health Research Institute, Sun City, Arizona 85372
  1. Correspondence: joseph.rogers{at}bannerhealth.com

Abstract

Biochemical and neuropathological studies of brains from individuals with Alzheimer disease (AD) provide clear evidence for an activation of inflammatory pathways, and long-term use of anti-inflammatory drugs is linked with reduced risk to develop the disease. As cause and effect relationships between inflammation and AD are being worked out, there is a realization that some components of this complex molecular and cellular machinery are most likely promoting pathological processes leading to AD, whereas other components serve to do the opposite. The challenge will be to find ways of fine tuning inflammation to delay, prevent, or treat AD.

Also in this Collection

    | Table of Contents

    Richard Sever interviews Joan Brugge